Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2021 vs. Q3 2021
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 56 | 1 | 53 | −2 |
| Shares | 34.9M | 40 | 36.3M | +1.45M (+4.1%) |
| Value | $759.4M | $0 | $742.0M | −$17.4M (−2.3%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ergoteles LLC | 74,510 | $1.52M | 0.06% |
| Prudential Financial Inc | 73,845 | $1.51M | 0.00% |
| EcoR1 Capital, LLC | 37,593 | $768.0K | 0.02% |
| Swiss National Bank | 25,600 | $523.0K | 0.00% |
| Allspring Global Investments Holdings, LLC | 15,543 | $317.0K | 0.00% |
| DekaBank Deutsche Girozentrale | 15,000 | $293.0K | 0.00% |
| UBS Group AG | 3,260 | $67.0K | 0.00% |
| Ensign Peak Advisors, Inc | 240 | $5.00K | 0.00% |
| Daiwa Securities Group Inc. | 136 | $3.00K | 0.00% |
Sold out (11)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Millennium Management LLC | 175,445 | $3.91M |
| Sphera Funds Management Ltd. | 119,647 | $2.67M |
| Logos Global Management LP | 50,000 | $1.11M |
| Caas Capital Management LP | 50,000 | $1.11M |
| Soleus Capital Management, L.P. | 25,000 | $557.0K |
| Ghisallo Capital Management LLC | 15,000 | $334.0K |
| Cubist Systematic Strategies, LLC | 10,731 | $239.0K |
| Rhumbline Advisers | 9,233 | $206.0K |
| MetLife Investment Management | 4,756 | $106.0K |
| Metropolitan Life Insurance Co | 3,598 | $80.2K |
| Piper Sandler & Co. | 2,300 | $51.0K |
Not filed for Q4 2021 yet (1)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Berman Capital Advisors, LLC | 40 | $0 |